Celldex Therapeutics
CLDX
CLDX
144 hedge funds and large institutions have $1.39B invested in Celldex Therapeutics in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 61 increasing their positions, 42 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
18% less capital invested
Capital invested by funds: $1.7B → $1.39B (-$311M)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
144
Holding in Top 10
3
Calls
$17.2M
Puts
$16.9M
Top Buyers
| 1 | +$16.5M | |
| 2 | +$10.6M | |
| 3 | +$8.27M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$6.85M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$6.23M |
Top Sellers
| 1 | -$35.8M | |
| 2 | -$12M | |
| 3 | -$6.27M | |
| 4 |
FAM
Fred Alger Management
New York
|
-$5.61M |
| 5 |
EP
Eversept Partners
New York
|
-$5.44M |